| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 08/26/2004 | WO2004004686A3 Cartilage enhancing food supplements and methods of preparing the same |
| 08/26/2004 | WO2004004653A3 Methods for treating psychosis associated with interferon-alpha therapy |
| 08/26/2004 | WO2003103585A3 Methods of treating angiogenesis, tumor growth, and metastasis |
| 08/26/2004 | WO2003101402A3 Methods of treating cognitive dysfunction by modulating brain energy metabolism |
| 08/26/2004 | WO2003090681A3 SYNERGISTIC EFFECTS OF NUCLEAR TRANSCRIPTION FACTOR NF-κB INHIBITORS AND ANTI-NEOPLASTIC AGENTS |
| 08/26/2004 | WO2003055440A3 Compositions and methods for the treatement of immune related diseases |
| 08/26/2004 | WO2003026567A3 Use of neuraminidase inhibitors to prevent flu associated bacterial infections |
| 08/26/2004 | WO2002030268A3 Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer |
| 08/26/2004 | WO2001051003A3 Use of lipid conjugates in the treatment of disease |
| 08/26/2004 | US20040167336 Octahydro-indolizine and quinolizine and hexahydro-pyrrolizine |
| 08/26/2004 | US20040167228 aerosols containing atenolol, pindolol, esmolol, propranolol, or metoprolol that are used in inhalation therapy |
| 08/26/2004 | US20040167219 Carnitine-magnesium hydroxycitrate |
| 08/26/2004 | US20040167204 Pharmacological agents and methods of treatment that inactivate pathogenic prokaryotic and eukaryotic cells and viruses by attacking highly conserved domains in structural metalloprotien and metalloenzyme targets |
| 08/26/2004 | US20040167202 Induction of immune tolerance |
| 08/26/2004 | US20040167201 Pyrrolidine melanocortin-specific compounds |
| 08/26/2004 | US20040167200 Inflammatory bowel disorders; pain therapy; anxiolytic agents; antidepressants; psychological disorders; autism; sleep disorders; amyotropic lateral sclerosis; cognition activators; eating disorders; administering nicotinic receptor antagonist |
| 08/26/2004 | US20040167197 Compositions, combinations, and methods for treating cardiovascular conditions and other associated conditions |
| 08/26/2004 | US20040167192 Modulate endothelia gene differentiation; antiproliferative agents; anticancer agents |
| 08/26/2004 | US20040167178 Combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes |
| 08/26/2004 | US20040167176 Tricyclic compounds useful as angiotensin II agonists |
| 08/26/2004 | US20040167160 Skin disorders; controlling cell differentiation; antidiabetic agents; cardiovascular disorders; anticancer agents; central nervous system disorders |
| 08/26/2004 | US20040167153 Synergistic mixture of phosphodiesterase inhibitor and adrenergic blocking agents; administering by breathing; respiratory system disorders; antiinflammatory agents |
| 08/26/2004 | US20040167145 moderator of cholinergic agent; mixture of acetylcholinesterase inhibitors and opioiod receptor blockers |
| 08/26/2004 | US20040167141 Anticancer agents; antidiabetic agents; Alzheimer's disease |
| 08/26/2004 | US20040167140 [5-carboxamido or 5-fluoro]-[2',3'-unsaturated or 3'-modified]-pyrimidine nucleosides |
| 08/26/2004 | US20040167139 Methods of treating cancer |
| 08/26/2004 | US20040167137 Xanthine phosphodiesterase V inhibitors |
| 08/26/2004 | US20040167134 Combination comprising n-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent |
| 08/26/2004 | US20040167133 Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4,3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| 08/26/2004 | US20040167125 such as sertindole, quetiapine and ziprasidone; use of combination to treat schizophrenia; synergistic mixture gives a more more rapid decrease in schizophrenic symptomology improving patient compliance |
| 08/26/2004 | US20040167108 Combination therapy of angiotensin converting enzyme inhibitor and aldosterone antagonist for reducing morbidity and mortality from cardiovascular disease |
| 08/26/2004 | US20040167101 Novel quinolinones and uses thereof |
| 08/26/2004 | US20040167097 Antiproliferative agents; using synergistic mixture of epothilone and nucleoside |
| 08/26/2004 | US20040167091 Methods for treating ocular neovascular diseases |
| 08/26/2004 | US20040167089 Immunostimulatory nucleic acid molecules |
| 08/26/2004 | US20040167081 Method for the prevention and treatment of cachexia and anorexia |
| 08/26/2004 | US20040167079 using 2-deoxyglucose to treat cancer and to improve patient outcome when administered at a therapeutically effective dose, optionally co-administered with other anti-cancer drugs, or in combination with surgical resection or radiation therapy |
| 08/26/2004 | US20040167065 human transferases and polynucleotides which identify and encode them; expression vectors, host cells, antibodies, agonists, and antagonists; diagnosing, treating, or preventing disorders associated with aberrant expression of the transferases |
| 08/26/2004 | US20040167064 Materials and methods relating for the treatment and diagnosis of pre-eclampsia |
| 08/26/2004 | US20040167039 containing polyol(s) and a gelling agent; increases in temperature by at least 5 degrees C. upon exposure to moisture and which has a Maximum Energy Release Index of at least 11 mJ/mg.; use for vaginal lubrication, administration of active ingredients and for preventing or treating dysmenorrhea |
| 08/26/2004 | US20040166561 Novel intein and uses thereof |
| 08/26/2004 | US20040166559 Vectors for gene therapy |
| 08/26/2004 | US20040166543 Regulation of cell growth by MUC1 |
| 08/26/2004 | US20040166536 Method for predicting whether subjects with mild cognitive impairment (MCI) will develop Alzheimer's Disease |
| 08/26/2004 | US20040166304 can be durably and firmly bonded to synthetic or living materials and used for medical and dental as well as technical applications |
| 08/26/2004 | US20040166177 Soluble plant extracts; concentrating active materials; mixture of carotenoids, anthocyanins, fatty acid, terpenes, and alkaloids; reducing concentration of sugars |
| 08/26/2004 | US20040166176 Side effect reduction; reducing pain; synergistic mixture containing muscle relaxants; administering prostaglandins |
| 08/26/2004 | US20040166175 Compositions and methods for nutrition supplementation |
| 08/26/2004 | US20040166162 Novel pharmaceutical formulation containing a proton pump inhibitor and an antacid |
| 08/26/2004 | US20040166136 Disinfecting mixture; aqueous solution of chlorite and acid |
| 08/26/2004 | US20040166115 Complex of protein and hapten-enzyme ; tumor antigen |
| 08/26/2004 | US20040166090 Antitumor agents; induction apoptosis |
| 08/26/2004 | DE10305070A1 Use of sodium-hydrogen ion antiporter 1 inhibitors e.g. N-(4,5-bis-methanesulfonyl-2-methyl-2-methyl-benzoyl)-guanidine, used at doses causing only partial inhibition, e.g. for treating arrhythmia or angina |
| 08/26/2004 | DE10303229A1 α-Liponsäure, Ambroxol und/oder Inhibitoren des Angiotensin Converting-Enzyms (ACE) umfassende Arzneimittel-Zubereitung und ihre Verwendung zur Behandlung von neurodegenerativen Erkrankungen α-lipoic acid, ambroxol and / or inhibitors of the angiotensin converting enzyme (ACE) comprehensive drug preparation and their use for the treatment of neurodegenerative diseases |
| 08/26/2004 | CA2516254A1 Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| 08/26/2004 | CA2515761A1 Use of artemisinin for treating tumors induced by oncogenic viruses and for treating viral infections |
| 08/26/2004 | CA2515676A1 Imidazopyridines containing combinations and their use in treating gastrointestinal inflammatory disorders |
| 08/26/2004 | CA2515594A1 Use of umbilical cord blood to treat individuals having a disease, disorder or condition |
| 08/26/2004 | CA2515534A1 New pharmaceutical compositions based on anticholinergics and tace-inhibitors |
| 08/26/2004 | CA2515530A1 New pharmaceutical compositions based on anticholinergics and inhibitors of tnf alpha synthesis or action |
| 08/26/2004 | CA2515407A1 Enhanced bioavailability of nutrients, pharmaceutical agents, and other bioactive substances through laser resonant homogenization or modification of molecular shape or crystalline form |
| 08/26/2004 | CA2515395A1 New pharmaceutical compositions based on anticholinergics and soluble tnf receptor fusion proteins |
| 08/26/2004 | CA2515391A1 Use of p-glycoprotein inhibitor surfactants at the surface of a colloidal carrier |
| 08/26/2004 | CA2514105A1 Chemical derivatives binding very specifically with g-quadruplex dna structures and use thereof as a specific anti-cancer agent |
| 08/26/2004 | CA2513668A1 Dyrks as modifiers of the apc and axin pathways and methods of use |
| 08/26/2004 | CA2488143A1 Methods and compositions for modulating glutamate transport activity in the nervous system |
| 08/25/2004 | EP1449540A1 Cytokine-inducing material and cytokine-inducing instrument |
| 08/25/2004 | EP1449528A1 Treatment of respiratory diseases |
| 08/25/2004 | EP1449522A1 A free radical quenching liposomal composition |
| 08/25/2004 | EP1449435A1 Anthelmintic composition |
| 08/25/2004 | EP1449432A1 Nonhuman model animal of systemic lupus erythematosus |
| 08/25/2004 | EP1448995A1 Assay for screening candidate drugs for the treatment of inflammatory diseases |
| 08/25/2004 | EP1448993A2 Detection of autoantibodies reactive with pancreatic islet cell antigenic molecules and/or insulin |
| 08/25/2004 | EP1448794A2 Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis |
| 08/25/2004 | EP1448790A2 Methods and compositions for treating cancer |
| 08/25/2004 | EP1448784A1 Antibiotics ge 81112 factors a, b, b1, pharmaceutically acceptable salts and compositions, and use thereof |
| 08/25/2004 | EP1448780A2 Direct targeting binding proteins |
| 08/25/2004 | EP1448771A1 A method for combined parallel agent delivery and electroporation for cell structures and use thereof |
| 08/25/2004 | EP1448770A1 A method for combined sequential agent delivery and electroporation for cell structures and use thereof |
| 08/25/2004 | EP1448753A2 Conditioning solution for contact lenses |
| 08/25/2004 | EP1448592A1 Steroidal compounds for inhibiting steroid sulphatase |
| 08/25/2004 | EP1448589A2 Sperm-specific cation channel, catsper2, and uses therefor |
| 08/25/2004 | EP1448588A2 Psma antibodies and protein multimers |
| 08/25/2004 | EP1448583A2 A novel g protein-coupled receptor, gave8 |
| 08/25/2004 | EP1448565A1 ADENOSINE A?2a? RECEPTOR ANTAGONISTS |
| 08/25/2004 | EP1448559A1 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione benzenesulfonate; process for its preparation; polymorphs i, ii and iii thereof; and its use as pharmaceutical active ingredient |
| 08/25/2004 | EP1448539A1 Hiv protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis |
| 08/25/2004 | EP1448534A1 6-membered unsaturated heterocyclic compounds useful for selective inhibition ofthe coagulation cascade |
| 08/25/2004 | EP1448504A2 Clusianon isomers and use thereof |
| 08/25/2004 | EP1448281A2 Therapeutic coating for an intravascular implant |
| 08/25/2004 | EP1448268A2 Use of an farnesyl protein transferase inhibitor in combination with other antineoplastic agents for the manufacture of a medicament against cancer |
| 08/25/2004 | EP1448237A1 Selective treatment of il-13 expressing tumors |
| 08/25/2004 | EP1448233A2 Endothelin antagonists ina method and composition for potentiating an opiate analgesic |
| 08/25/2004 | EP1448232A1 Anti-proliferative composition |
| 08/25/2004 | EP1448231A1 Topical delivery of codrugs |
| 08/25/2004 | EP1448228A2 Management of postoperative pain |
| 08/25/2004 | EP1448224A2 Use of selectin-binding active ingredients for the treatment of inflammatory and tumoral diseases |
| 08/25/2004 | EP1448217A1 Methods for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism |
| 08/25/2004 | EP1448210A2 REGULATION OF cGMP-SPECIFIC PHOSPHODIESTERASE 9A |
| 08/25/2004 | EP1448205A2 Combinations for the treatment of immunoinflammatory disorders |